Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva®) and Gefitinib (Iressa®)

Oncologist

Volumn 10, Issue 8, 2005, Pages 579-589

  Siegel Lakhai, Wandena S ^a,b,d   Beijnen, Jos H ^a,b,c   Schellens, Jan H M ^a,b,c  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

EGFR tyrosine kinase inhibitors; Erlotinib; Gefitinib; Targeted therapy EGFR tyrosine kinase domain mutations

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; BILIRUBIN; CAPECITABINE; CARBAMAZEPINE; CELECOXIB; CIMETIDINE; CYTOCHROME P450 3A4; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FAMOTIDINE; GEFITINIB; KETOCONAZOLE; OMEPRAZOLE; OXALIPLATIN; PHENYTOIN; PLACEBO; RANITIDINE; RIFAMPICIN;

ACNE; ADVANCED CANCER; AMBLYOPIA; ANOREXIA; AREA UNDER THE CURVE; ASTHENIA; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; CONJUNCTIVITIS; COUGHING; DIARRHEA; DRUG ABSORPTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRY SKIN; DYSPNEA; ENZYME INHIBITION; FATIGUE; FEVER; FUTUROLOGY; GENE MUTATION; HIGH RISK PATIENT; HUMAN; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; MOUTH ULCER; NAUSEA; PERIPHERAL EDEMA; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; SIDE EFFECT; STOMATITIS; SYSTEMATIC REVIEW; VOMITING; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; FEMALE; FORECASTING; HUMANS; LUNG NEOPLASMS; MALE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 26444519872     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.10-8-579     Document Type: Review

References (70)

1. Fantl WJ, Johnson DE, Williams LT. Signalling by receptor tyrosine kinases. Annu Rev Biochem 1993;62:453-481.
2. Brabender J, Danenberg KD, Metzger R et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001;7:1850-1855.
3. Rubin Grandis J, Melhem MF, Gooding WE et al. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90:824-832.
4. Baselga J. New technologies in epidermal growth factor receptor-targeted cancer therapy. Signal 2000;1:12-21.
5. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999;82:241-250.
6. Meyers MB, Shen WP, Spengler BA et al. Increased epidermal growth factor receptor in multidrug-resistant human neuroblastoma cells. J Cell Biochem 1988;38:87-97.
7. Ritter CA, Arteaga CL. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin Oncol 2003;30(suppl 1):3-11.
8. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. The Oncologist 2002;7(suppl 4):2-8.
9. Brehmer D, Greff Z, Godl K et al. Cellular targets of gefitinib. Cancer Res 2005;65:379-382.
10. Ranson M. ZD1839(Iressa™); for more than just non-small celllung cancer. The Oncologist 2002;7(suppl 4):16-24.
11. Herbst RS, Maddox AM, Rothenberg ML et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small cell lung cancer and other solid tumors: results of aphase I trial. J Clin Oncol 2002;20:3815-3825.
12. Giaccone G. Herb1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. Ann Oncol 2005;16:538-548.
13. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004;22:777-784.
14. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004;22:785-794.
15. Gatzemeier U, Pluzanska A, Szczesna E et al. Results of a phase II trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004;22:7010.
16. Herbst RS, Prager D, Hermann R et al. TRIBUTE-a phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004;22:7011.
17. Friedmann B, Caplin M, Hartley JA et al. Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839). Clin Cancer Res 2004;10:6476-6486.
18. Akita RW, Sliwkowski MX. Preclinical studies with erlotinib (Tarceva). Semin Oncol 2003;30(suppl 7):15-24.
19. Fukuoka M, Yano S, Giaccone G et al. Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non-small-cell lung cancer (IDEAL1). Proc Am Soc Clin Oncol 2002;21:298a.
20. Kris MG, Natale RB, Herbst RS et al. A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL2). Proc Am Soc Clin Oncol 2002;21:292a.
21. Perez-Soler R, Chachoua A, Huberman M et al. Final results of a phase II study of erlotinib (Tarceva) monotherapy in patients with advanced non-small cell lung cancer following failure of platinum based chemotherapy. Lung Cancer 2003;41(suppl 2):S246.
22. Perez-Soler R. Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. Clin Lung Cancer 2004;6(suppl 1):S20-S23.
23. Patel JD, Miller VA, Kris MG et al. Encouraging activity and durable responses demonstrated by the EGFR tyrosine kinase inhibitor erlotinib (Tarceva, OSI-774) in patients with advanced bronchoalveolar (BAC) cell carcinoma. Lung Cancer 2003;41(suppl):S56.
24. West HL, Franklin WA, Grumerlock P et al. ZD1839 (Iressa) in advanced bronchoalveolar carcinoma(BAC): a preliminary report of SWOG S0126. Lung Cancer 2003;41(suppl):S56.
25. Twombly R. Failing survival advantage in crucial trial, future of Iressa in jeopardy. J Natl Cancer Inst 2005;97:249-250.
26. Fuster LM, Sandler AB. Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes. Clin Lung Cancer 2004;6(suppl 1):S24-S29.
27. Albanell J, Rojo F, Averbuch S et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002;20:110-124.
28. Mohamed MK, Ramalingam S, Lin Y et al. Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. Ann Oncol 2005;16:780-785.
29. Knezevic KK, Iwata G, Baibakova J et al. Development of a HER1 assay using individual human hair follicles. Proc Am Soc Clin Oncol 2004;23:3044.
30. Baselga J, Rischin D, Ranson M et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002;20:4292-4302.
31. Soulieres D. Identifying predictive and surrogate markers of erlotinib antitumor activity other than rash. Oncology (Williston Park) 2003;17(suppl 12):29-33.
32. Hirsch FR, Witta S. Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer. Curr Opin Oncol 2005;17:118-122.
33. Pao W, Wang TY, Riely GJ. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib and erlotinib. PLoS Med 2005;2:57-61.
34. Kelly H, Ferry D, Hammond L et al. ZD1839 (Iressa), an oral EGFR-TKI (epidermal growth factor receptor tyrosine kinase inhibitor): pharmacokinetic results of a phase I study in patients with advanced cancer. Proc Am Assoc Cancer Res 2000;41:612.
35. Kris M, Ranson M, Ferry D et al. Phase I study of oral ZD1839 (Iressa), a novel inhibitor of epidermal growth factor tyrosine kinase (EGFR-TK): evidence of good tolerability and activity. Clin Cancer Res 1999;5(suppl):3749s.
36. Sandler A. Clinical experience with HER1/EGFR tyrosine kinase inhibitor erlotinib. Oncology (Williston Park) 2003;17(suppl 12):17-22.
37. U.S. Food and Drug Administration. Tarceva® (erlotinib tablets). Washington, DC: US Government Printing Office; 2004:1-21.
38. Hidalgo M, Siu LL, Nemunaitis J et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, inpatients with advanced solid malignancies. J Clin Oncol 2001;19:3267-3279.
39. U.S. Food and Drug Administration. Iressa® (gefitinib tablets). Washington, DC: US Government Printing Office; 2003:1-15.
40. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-2970.
41. Camus PH, Foucher P, Bonniaud PH et al. Drug-induced infiltrative lung disease. Eur Respir J Suppl 2001;32:93s-100s.
42. McCune JS, Hawke RL, LeCluyse EL et al. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther 2000;68:356-366.
43. Wakeling AE, Guy SP, Woodburn JR et al. ZD1839 (Iressa®): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002;62:5749-5754.
44. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
45. Bardelli A, Parsons DW, Silliman N et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 2003;300:949.
46. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-13311.
47. Shigematsu H, Lin L, Takahashi T et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-346.
48. Sordella R, Bell DW, Haber DA et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305:1163-1167.
49. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005;23:2556-2568.
50. Mitsudomi T, Kosaka T, Endoh H et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005;23:2513-2520.
51. Tokumo M, Toyooka S, Kiura K et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 2005;11:1167-1173.
52. Sauter G, Maeda T, Waldman FM et al. Patterns of epidermal-growth factor receptor amplification in malignant gliomas. Am J Pathol 1996;148:1047-1053.
53. Kobayashi S, Boggon TJ, Dayaram T et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-792.
54. Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73. Epub 2005 Feb 22.
55. Blagosklonny MV, Darzynkiewicz Z. Why Iressa failed: towards novel use of kinase inhibitors. Cancer Biol Ther 2003;2:137-140.
56. Perez-Soler R, Piperdi B, Haigentz M et al. Determinants of sensitivity to the EGFR TK inhibitor erlotinib (E) in a panel of NSCLC cell lines. Proc Am Soc Clin Oncol 2004;23:7026.
57. Bianco R, Shin I, Ritter CA et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003;22:2812-2822.
58. Ranson M, Hammond LA, Ferry D et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002;20:2240-2250.
59. Perez-Soler R. The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer. Clin Cancer Res 2004;10:4238s-4240s.
60. Kwak EL, Sordella R, Bell DW et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 2005;102:7665-7670.
61. Fisher GA, Kuo T, Cho CD et al. A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2004;23:3514.
62. Wirth LJ, Haddad RI, Wieczorek J et al. Phase I study of gefitinib plus celecoxib in patients with metastatic and/or locally recurrent squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol 2004;23:5540.
63. Delord JP, Beale P, Van Cutsem E. A phase Ib dose-escalation trial of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer (MCRC) patients. Proc Am Soc Clin Oncol 2004;23:3585.
64. Mauer AM, Cohen EEW, Wong SJ et al. Phase I study of epidermal growth factor receptor (EGFR) inhibitor, erlotinib, and vascular endothelial growth factor monoclonal antibody, bevacizumab, in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol 2004;23:5539.
65. Bozec A, Hofman P, Gugenheim J et al. Combined effect of gefitinib (Iressa), with ZD6126, an antivascular drug, and radiotherapy (Rt) on head and neck tumors, an in vivo study. Proc Am Assoc Cancer Res 2005;46:2305.
66. Tanaka T. Inhibition of DNA repair in the radiosensitization of NSCLC cells by gefitinib, a specific EGFR-inhibitor. Proc Am Assoc Cancer Res 2005;46:1994.
67. Cohen MH., Johnson JR., Chen Y-F et al. FDA drug approval summary: erlotinib (Tarceva®) tablets. The Oncologist 2005;10:461-466.
68. Comis RL. The current situation: erlotinib (Tarceva®) and gefitinib (Iressa®) in non-small cell lung cancer. The Oncologist 2005;10:467-470.
69. EMEA: European Medicines Agency; Pre-Authorisation Evaluation of Medicines for/Human Use for Tarceva. EMEA/CHMP/133846/2005. June 23, 2005.
70. Taron M, Ichinose Y, Resell R et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 2005;11:5878-5885.